Drugs that contain Glycopyrrolate; Indacaterol Maleate
1. List of Utibron drug patents
UTIBRON's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(1 year, 8 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) | |
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
More Information on Dosage
UTIBRON family patents
15
United States
12
United Kingdom
9
European Union
8
Japan
6
China
5
Canada
5
Australia
3
Brazil
3
Spain
3
New Zealand
3
Norway
3
Russia
2
Poland
2
Slovenia
2
Korea, Republic of
2
Hong Kong
2
Cyprus
2
Denmark
2
South Africa
2
Austria
2
Portugal
2
Singapore
1
Taiwan
1
Morocco
1
Germany
1
Malaysia
1
Argentina
1
Mexico
1
Ecuador
1
Tunisia
1
Israel
1
Peru
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic